Latest Tax Incentives News

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

COG Financial Services reported solid half-year results with an 8% rise in underlying revenue and a 14% increase in profit after tax, driven by acquisitions and expanded equity stakes. The company also announced a fully franked interim dividend of 3.5 cents per share.

FortifAI Limited reported a 51% revenue decline but a 70% reduction in net loss for H1 FY26, alongside completing a major AI technology acquisition and securing $5 million in fresh capital.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Barton Gold Holdings has distributed over $640,000 in Junior Minerals Exploration Incentive tax credits to investors from its June 2025 placement, enhancing returns amid strong exploration activity.